Intact Investment Management Inc. Acquires Shares of 9,700 Becton, Dickinson and Company (NYSE:BDX)

Intact Investment Management Inc. bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,700 shares of the medical instruments supplier's stock, valued at approximately $2,365,000.

Other hedge funds have also recently bought and sold shares of the company. OFI Invest Asset Management acquired a new stake in Becton, Dickinson and Company during the third quarter worth approximately $25,000. Fortitude Family Office LLC acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $35,000. Venturi Wealth Management LLC boosted its position in Becton, Dickinson and Company by 552.0% during the fourth quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 138 shares during the last quarter. Arlington Trust Co LLC acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $41,000. Finally, Headlands Technologies LLC acquired a new stake in Becton, Dickinson and Company during the third quarter worth approximately $55,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Activity

In other news, SVP Thomas J. Spoerel sold 282 shares of the firm's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares of the company's stock, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.31% of the company's stock.

Becton, Dickinson and Company Trading Up 0.5 %

NYSE:BDX traded up $1.07 during trading hours on Friday, reaching $231.55. 738,154 shares of the company were exchanged, compared to its average volume of 1,001,849. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64. The firm has a market cap of $66.90 billion, a price-to-earnings ratio of 54.87, a PEG ratio of 1.91 and a beta of 0.43. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32. The stock has a 50 day simple moving average of $239.24 and a 200 day simple moving average of $241.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating analysts' consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. During the same quarter last year, the firm posted $2.98 EPS. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, analysts predict that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on BDX shares. Barclays raised their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an "overweight" rating in a research report on Monday, February 5th. Raymond James increased their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 3rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.